#REJOIN MEDICAL SKIN#

FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.Ī core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. Approximately $20.1 trillion is currently benchmarked to FTSE Russell indexes. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.įTSE Russell index expertise and products are used extensively by institutional and retail investors globally. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications.įTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. Delivered at the point-of-care, RECELL enables improved clinical outcomes.

#REJOIN MEDICAL SKIN#

The RECELL ® System technology platform, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects and for repigmentation of stable depigmented vitiligo lesions, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. Russell indexes are part of FTSE Russell, a leading global index provider.įor more information on the Russell 3000 Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.Īuthorized for release by the Chief Executive Officer of AVITA Medical, Inc.ĪVITA Medical ® is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration.

Approximately $12.1 trillion in assets are benchmarked against Russell’s U.S. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. “We believe our inclusion will expand our exposure to the investment community and broaden our investor base, further advancing our strategic growth initiatives.” “We are pleased to rejoin the globally recognized Russell indexes,” said Jim Corbett, Chief Executive Officer of AVITA Medical. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. stocks as of April 28, 2023, ranking them by total market capitalization, including both the Russell 3000 and Russell Microcap ® Indexes. The annual Russell indexes reconstitution captures the 4,000 largest U.S. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it has rejoined the broad-market Russell 3000 ® Index following the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. VALENCIA, Calif., and MELBOURNE, Australia, J(GLOBE NEWSWIRE) - AVITA Medical, Inc.

Rejoin medical